Multicentric Castleman disease: consensus at last?
نویسندگان
چکیده
منابع مشابه
Multicentric Castleman disease: consensus at last?
In collaboration with an international cohort of clinicians and pathologists who reviewed more than 240 cases, the authors concurred on a set of evidence-based criteria, thereby paving the way for a uniform approach to managing this enigmatic condition. In 1956, Castleman et al described clinicopathologic features of 13 asymptomatic patients who presented with a mediastinal mass. This form of u...
متن کاملChronic Myelomonocytic Leukemia following Multicentric Castleman Disease
Multicentric Castleman disease (MCD) is a rare nonmalignant lymphoproliferative disorder presenting systemic symptoms such as fever, night sweats, fatigue, anemia, effusions, and multifocal lymphadenopathy. The etiology of MCD has not been clarified to date. The coexistence of MCD with chronic myelomonocytic leukemia (CMML) has been rarely reported. Although the pathogenesis remains unclear, th...
متن کاملSiltuximab for Multicentric Castleman Disease-Letter.
We read with great interest the article by Deisseroth and colleagues (1) focusing on the recent global approval of the monoclonal IL6 antibody siltuximab for the treatment of patients with HHV-8-, HIV-negative multicentric Castleman disease (MCD). Up to now, treatment options for this rare lymphoproliferative disorder are very limited. Lately, the phase III, double-blind, randomized trial of va...
متن کاملInternational, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.
Human herpesvirus-8 (HHV-8)-negative, idiopathic multicentric Castleman disease (iMCD) is a rare and life-threatening disorder involving systemic inflammatory symptoms, polyclonal lymphoproliferation, cytopenias, and multiple organ system dysfunction caused by a cytokine storm often including interleukin-6. iMCD accounts for one third to one half of all cases of MCD and can occur in individuals...
متن کاملSerum viral interleukin-6 in AIDS-related multicentric Castleman disease.
activated protein C and factor V Leiden as risk factors for venous thrombosis. Thromb Haemost. 1995;74:449-453. 5. Williamson D, Brown K, Luddington R, Baglin C, Baglin T. Factor V Cambridge: a new mutation (Arg3063Thr) associated with resistance to activated protein C. Blood. 1998;91:1140-1144. 6. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in use...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood
سال: 2017
ISSN: 0006-4971,1528-0020
DOI: 10.1182/blood-2017-01-763482